



SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

“Transcriptional regulatory network of T-cell controlling type 1 interferon response in COVID-19”

Tomokazu Sumida, MD, PhD

Assistant Professor of Neurology, Yale School of Medicine

Tuesday, February 16, 2021 from 4-4:30 P.M.

<https://yale.zoom.us/j/96142024981?pwd=anJnZE8yMlhjL1JpL2ZrVWMzbW9Qdz09>

Password: HTI

Meeting ID: 961 4202 4981

(Or join by telephone: 203-432-9666)

CME credit: Text 22206 to 203-442-9435

Host: Dr. David Hafler

Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will understand:

1. Human T cell transcriptional regulation upon type 1 IFN
2. Impact of type 1 IFN on co-inhibitory receptor expression on T cells
3. Potential novel targets to manipulate type 1 IFN response to treat COVID-19

FACULTY DISCLOSURES

Tomokazu Sumida: None

Carrie Lucas: None

Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.



SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

“COVID-19 in children”

Kevan Herold, MD

C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology), Yale School of Medicine

Tuesday, February 16, 2021 from 4:30-5 P.M.

<https://yale.zoom.us/j/96142024981?pwd=anJnZE8yMlhjL1JpL2ZrVWMzbW9Qdz09>

Password: HTI

Meeting ID: 961 4202 4981

(Or join by telephone: 203-432-9666)

CME credit: Text 22206 to 203-442-9435

Host: Dr. David Hafler

Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will:

1. Be aware of the difference in the clinical outcomes of COVID-19 in children and adults
2. Learn about cellular, humoral, and cytokine differences between children and adults with COVID-19
3. Identify differences in the responses in the nasopharynx between children and adults to SARS-CoV-2

FACULTY DISCLOSURES

Kevan Herold: None
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs